A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing

Author： Meckley Lisa M.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.28, Iss.1, 2010-01, pp. : 61-74

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical interest of point-of-care pharmacogenomic testing: clopidogrel behind warfarin

By Shahabi Payman   Siest Gérard   Visvikis-Siest Sophie  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1215-1218

Future Medicine

Access to resources Recommend Favorite

Regulatory Plans for Risks, Benefits, and Costs

By Carr C.J.  

Regulatory Toxicology and Pharmacology, Vol. 23, Iss. 3, 1996-06 ,pp. : 177-177

Academic Press

Access to resources Recommend Favorite

Direct-to-consumer pharmacogenomic testing

By Howard Heidi Carmen   Borry Pascal  

Pharmacogenomics, Vol. 12, Iss. 10, 2011-10 ,pp. : 1367-1370

Future Medicine

Access to resources Recommend Favorite

Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 9, Iss. 2, 2011-06 ,pp. : 94-101

Bentham Science Publishers

Access to resources Recommend Favorite

HIV-1 contacting and testing policy cuts PEP prescribing, costs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 366, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite